Rockefeller Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-375
Closed 4227
2022
Q4
$0 Sell
375
-6,000
-94% -$3.95K ﹤0.01% 4375
2022
Q3
$7K Buy
6,375
+2,000
+46% +$3.12K ﹤0.01% 3253
2022
Q2
$7K Sell
4,375
-1,125
-20% -$1.66K ﹤0.01% 3335
2022
Q1
$11K Sell
5,500
-500
-8% -$982 ﹤0.01% 3022
2021
Q4
$16K Sell
6,000
-4,000
-40% -$14.8K ﹤0.01% 2770
2021
Q3
$44K Sell
10,000
-7,800
-44% -$37.6K ﹤0.01% 2201
2021
Q2
$103K Buy
17,800
+4,300
+32% +$25.2K ﹤0.01% 1788
2021
Q1
$94K Buy
13,500
+12,674
+1,534% +$85K ﹤0.01% 1627
2020
Q4
$3K Buy
826
+326
+65% +$1.65K ﹤0.01% 2606
2020
Q3
$2K Hold
500
﹤0.01% 2438
2020
Q2
$3K Hold
500
﹤0.01% 2280
2020
Q1
$3K Hold
500
﹤0.01% 2134
2019
Q4
$5K Buy
+500
New +$3.64K ﹤0.01% 1803

Other funds holding CLVS

Rockefeller Capital Management's CLVS Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2023, closing a stake of 375 shares.

Rockefeller Capital Management first reported a position in CLVS in Q4 2019 and held it in 13 quarters. The position peaked at $103K in Q2 2021. 2 funds tracked by Wall St. Rank hold CLVS as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Clovis Oncology, Inc. position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 375 Clovis Oncology, Inc. shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in Clovis Oncology, Inc. in Q4 2019 and held it in 13 quarters.
  • Rockefeller Capital Management's Clovis Oncology, Inc. position peaked at $103K in Q2 2021.
  • 2 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.